Key facts
- Yuandao Pharmaceutical’s last known valuation is $23.2M (Feb 2021).
- It has raised $2.3M; the latest was Early Stage VC in Dec 2024.
- Notable investors include Aurisco Pharmaceutical, Kangcheng Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Yuandao Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Yuandao Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yuandao Pharmaceutical
Developer of innovative chronic disease drugs designed for precise and intelligent drug design in chronic disease treatment. The company provides efficient drug discovery and personalized therapy solutions, enabling healthcare professionals and patients with advanced, targeted treatments for chronic diseases.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Yuandao Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yuandao Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yuandao Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.